Nikko Asset Management Americas’s Cellular Biomedicine Group, Inc. CBMG Stock Holding History

Nikko Asset Management Americas’s Portfolio CBMG Stock Details CBMG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-476,673	Closed	-$7.54M	–	179
2020 Q1	$7.54M	Sell	476,673 -56,152	-11%	-$907K	0.14%	88
2019 Q4	$8.65M	Sell	532,825 -24,927	-4%	-$416K	0.14%	98
2019 Q3	$8.29M	Buy	557,752 +25,434	+5%	+$343K	0.15%	98
2019 Q2	$8.8M	Buy	532,318 +143,798	+37%	+$2.35M	0.17%	89
2019 Q1	$6.72M	Buy	+388,520	New	+$7.05M	0.18%	93

Other funds holding CBMG

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PIM

Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return

Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return

Nikko Asset Management Americas's CBMG Position: Q2 2020 in Review

Nikko Asset Management Americas sold out of Cellular Biomedicine Group, Inc. (CBMG) in Q2 2020, closing a stake of 476,673 shares — an estimated $7.54M sold.

Nikko Asset Management Americas first reported a position in CBMG in Q1 2019 and held it in 5 quarters. The position peaked at $8.8M in Q2 2019. 45 funds tracked by Wall St. Rank hold CBMG as of Q2 2020.

Nikko Asset Management Americas reported no remaining Cellular Biomedicine Group, Inc. position as of Q2 2020 after selling out during the quarter.
Nikko Asset Management Americas sold 476,673 Cellular Biomedicine Group, Inc. shares in Q2 2020, an estimated $7.54M.
Nikko Asset Management Americas first reported a position in Cellular Biomedicine Group, Inc. in Q1 2019 and held it in 5 quarters.
Nikko Asset Management Americas's Cellular Biomedicine Group, Inc. position peaked at $8.8M in Q2 2019.
45 funds tracked by Wall St. Rank held Cellular Biomedicine Group, Inc. as of Q2 2020.

Based on Nikko Asset Management Americas's 13F filing for Q2 2020, filed 7 Aug 2020.